TechsoMed

TechsoMed develops advanced medical technology, specializing in real-time predictive visualization systems for tissue response during ablation procedures, enhancing surgical precision and patient care. Founded in 2012 and headquartered in Rehovot, Israel, TechsoMed focuses on innovative medical solutions. The company raised USD 7. 00 mn in its Series B funding round in March 2021, led by Axil Capital Partners, with participation from Johnson & Johnson Innovation and NextLeap Ventures among others.

CEO Yossi Abu has been instrumental in steering the company’s strategic direction, emphasizing its growth in the healthcare sector. TechsoMed primarily offers its flagship product, BioTrace™, which provides real-time predictive visualization of tissue response during ablation procedures. BioTrace™ uses advanced algorithms to monitor tissue behavior during thermal ablation, aiming to improve surgical outcomes by minimizing damage to healthy tissues. The technology is applicable in oncology, particularly for liver tumor ablation, and is being evaluated for use in cardiovascular treatments and pain management.

The products are marketed to healthcare providers and hospitals in regions such as the United States and Japan. TechsoMed generates revenue through the sale and licensing of its BioTrace™ technology, which is utilized in healthcare settings to improve patient care in ablation treatments. The company engages in partnerships with hospitals, offering software solutions like the recently FDA-cleared BioTrace software. Revenue models include upfront licensing fees and ongoing service agreements, designed to integrate smoothly into current workflows without requiring additional hardware investments.

In March 2021, TechsoMed raised USD 7. 00 mn in Series B funding to facilitate the scaling of its technology and support expansion into new markets. The company plans to enhance its product offerings and is likely to focus on expanding its reach in the United States and Japan, aiming for broader adoption of its BioTrace™ technology. The recent funding will help accelerate these initiatives, allowing TechsoMed to explore further development of its solutions to meet increasing demand in the healthcare sector.